A novel, long-acting glucagon-like peptide receptor-agonist: dulaglutide

References

• TurnerRCullCHolmanRUnited Kingdom prospective diabetes study 17: a 9-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non-insulin-dependent diabetes mellitusAnn Intern Med19961241 Pt 2136 1458554206
   PubMed Web of Science ®Google Scholar
• Internation diabetes federation (IDF)Diabetes Atlas6th edBrussels, BelgiumIDF2013 Available from: http://www.idf.org/diabetesatlasAccessed December 1, 2014
   Google Scholar
• NathanDMBuseJBDavidsonMBMedical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of DiabetesDiabetes Care2009321193 20318945920
   PubMed Web of Science ®Google Scholar
• InzucchiSEBergenstalRMBuseJBManagement of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of DiabetesDiabetes Care2015381140 14925538310
   PubMed Web of Science ®Google Scholar
• BaggioLLHuangQBrownTJDruckerDJA recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasisDiabetes20045392492 250015331566
   PubMed Web of Science ®Google Scholar
• NauckMAKleineNOrskovCHolstJJWillmsBCreutzfeldtWNormalization of fasting hyperglycemia by exogenous glucagon-like peptide 1 (7–36 amide) in type 2 (non-insulin-dependent) diabetic patientsDiabetologia1993368741 7448405741
   PubMed Web of Science ®Google Scholar
• AmoriRELauJPittasAGEfficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysisJAMA20072982194 20617622601
   PubMed Web of Science ®Google Scholar
• BarnettAHNew treatments in type 2 diabetes: a focus on the incretin-based therapiesClin Endocrinol2009703343 353
   Web of Science ®Google Scholar
• MonamiMMarchionniNMannucciEGlucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trialsEur J Endocrinol20091606909 91719318378
   PubMed Web of Science ®Google Scholar
• NorrisSLLeeNThakurtaSChanBKExenatide efficacy and safety: a systematic reviewDiabet Med2009269837 84619719703
   PubMed Web of Science ®Google Scholar
• ShyangdanDSRoylePLClarCSharmaPWaughNRGlucagon-like peptide analogs for type 2 diabetes mellitus: systematic review and meta-analysisBMC Endocr Disord2010102021143938
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence (NICE)Type 2 Diabetes: The Management of Type 2 Diabetes; NICE Clinical Guideline 87London, UKNICE2014 Available from: http://www.nice.org.uk/cg87Accessed December 1, 2014
   Google Scholar
• European Medicines Agency (EMA)Trulicity. Summary of Product CharacteristicsLondon, UKEMA2014 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002825/WC500179470.pdfAccessed May 5, 2015
   Google Scholar
• European Medicines Agency (EMA)EPAR TrulicityLondon, UKEMA2014 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002825/WC500179473.pdfAccessed January 5, 2015
   Google Scholar
• Eli LillyFDA Approves Trulicity (Dulaglutide), Lilly’s Once Weekly Therapy for Adults with Type 2 DiabetesIndianapolis, INEli Lilly2014 Available from: https://investor.lilly.com/releasedetail.cfm?ReleaseID=871658Accessed October 1, 2014
   Google Scholar
• ShyangdanDSRoylePClarCSharmaPWaughNSnaithAGlucagon-like peptide analogs for type 2 diabetes mellitusCochrane Database Syst Rev201110Cd00642321975753
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence (NICE)NICE CG66. Type 2 Diabetes (Partially Updated by CG87)London, UKNICE2008 Available from: http://www.nice.org.uk/guidance/cg66Accessed December 12, 2014
   Google Scholar
• Scottish Intercollegiate Guidelines Network (SIGN)Management of Diabetes A National Guideline SIGN 116Edinburgh, ScotlandSIGN2010 Available from: http://www.sign.ac.uk/pdf/sign116.pdfAccessed December 10, 2014
   Google Scholar
• National Institute for Health and Care Excellence (NICE)Type 2 Diabetes in Adults: Management of Type 2 Diabetes in Adults. NICE Guideline Draft for Consultation, January 2015London, UKNICE2015 Available from: http://www.nice.org.uk/Guidance/InDevelopment/GID-CGWAVE0612Accessed February 10, 2015
   Google Scholar
• DunganKMPovedanoSTForstTOnce-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomized, open-label, phase 3, non-inferiority trialLancet201438499511349 135725018121
   PubMed Web of Science ®Google Scholar
• GiorginoFBenroubiMSunJHZimmermannAGPechtnerVEfficacy and safety of once-weekly dulaglutide vs insulin glargine in combination with metformin and glimepiride in type 2 diabetes patients (AWARD-2)Diabetes201463A87
   Web of Science ®Google Scholar
• NauckMWeinstockRSUmpierrezGEGuerciBSkrivanekZMilicevicZEfficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5)Diabetes Care20143782149 215824742660
   PubMed Web of Science ®Google Scholar
• WyshamCBlevinsTArakakiREfficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1)Diabetes Care20143782159 216724879836
   PubMed Web of Science ®Google Scholar
• JendleJRosenstockJBlondeLBetter glycemic control and less weight gain with once-weekly dulaglutide vs. once-daily insulin glargine, both combined with premeal insulin lispro, in type 2 diabetes patients (AWARD-4)Diabetes201463A246 A247
   Web of Science ®Google Scholar
• Eli LillyA study in participants with type 2 diabetes mellitus (AWARD-2) Available from: https://clinicaltrials.gov/ct2/show/NCT01075282?term=NCT01075282&rank=1. NLM identifier: NCT01075282Accessed May 30, 2015
   Google Scholar
• UmpierrezGPovedanoSTManghiFPShurzinskeLPechtnerVEfficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3)Diabetes Care20143782168 217624842985
   PubMed Web of Science ®Google Scholar
• GrunbergerGChangAGarcia SoriaGBotrosFTBsharatRMilicevicZMonotherapy with the once-weekly GLP-1 analog dulaglutide for 12 weeks in patients with Type 2 diabetes: dose-dependent effects on glycemic control in a randomized, double-blind, placebo-controlled studyDiabet Med201229101260 126722804250
   PubMed Web of Science ®Google Scholar
• TerauchiYSatoiYTakeuchiMImaokaTMonotherapy with the once weekly GLP-1 receptor agonist dulaglutide for 12 weeks in Japanese patients with type 2 diabetes: dose-dependent effects on glycemic control in a randomized, double-blind, placebo-controlled studyEndocr J20146110949 95925029955
   PubMed Web of Science ®Google Scholar
• WaughNCumminsERoylePNewer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluationHealth Technol Assess201014361 248
   Web of Science ®Google Scholar
• RichterBBandeira-EchtlerEBergerhoffKLerchCLDipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitusCochrane Database Syst Rev20082Cd00673918425967
   PubMed Web of Science ®Google Scholar
• GarberAJKingABDel PratoSInsulin degludec, an ultralongacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomized, open-label, treat-to-target non-inferiority trialLancet201237998251498 150722521072
   PubMed Web of Science ®Google Scholar
• ZinmanBPhilis-TsimikasACariouBInsulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long)Diabetes Care201235122464 247123043166
   PubMed Web of Science ®Google Scholar
• Philis-TsimikasADel PratoSSatmanIEffect of insulin degludec versus sitagliptin in patients with type 2 diabetes uncontrolled on oral antidiabetic agentsDiabetes Obes Metab2013158760 76623577643
   PubMed Web of Science ®Google Scholar
• GaleEIncretin therapy: should adverse consequences have been anticipated?BMJ2013346f361723751905
   PubMed Web of Science ®Google Scholar
• LiLShenJBalaMMIncretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomized and non-randomized studiesBMJ2014348g236624736555
   PubMed Web of Science ®Google Scholar
• FaillieJLAzoulayLPatenaudeVHillaire-BuysDSuissaSIncretin based drugs and risk of acute pancreatitis in patients with type 2 diabetes: cohort studyBMJ2014348g278024764569
   PubMed Web of Science ®Google Scholar
• MontoriVMThe safety of incretin based drugsBMJ2014348g277924764568
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration (FDA)Summary Review DulaglutideSilver Spring, MDFDA2014 Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/125469Orig1s000SumR.pdfAccessed January 5, 2015
   Google Scholar
• RobinsonLEHoltTAReesKRandevaHSO’HareJPEffects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysisBMJ Open201331
   Web of Science ®Google Scholar
• MadsbadSKielgastUAsmarMDeaconCFTorekovSSHolstJJAn overview of once-weekly glucagon-like peptide-1 receptor agonists – available efficacy and safety data and perspectives for the futureDiabetes Obes Metab2011135394 40721208359
   PubMed Web of Science ®Google Scholar
• GustavsonSMChenDSomayajiVEffects of a long-acting GLP-1 mimetic (PF-04603629) on pulse rate and diastolic blood pressure in patients with type 2 diabetes mellitusDiabetes Obes Metab201113111056 105821812891
   PubMed Web of Science ®Google Scholar
• FerdinandKCWhiteWBCalhounDAEffects of the once-weekly glucagon-like peptide-1 receptor agonist dulaglutide on ambulatory blood pressure and heart rate in patients with type 2 diabetes mellitusHypertension2014644731 73724980665
   PubMed Web of Science ®Google Scholar
• TrainaANLullMEHuiACZahorianTMLyons-PattersonJOnce-weekly exenatide as adjunct treatment of type 1 diabetes mellitus in patients receiving continuous subcutaneous insulin infusion therapyCan J Diabetes2014384269 27224797495
   PubMed Web of Science ®Google Scholar
• BainSCSkrivanekZTahbazAPechtnerVAdetunjiOEfficacy of long-acting once weekly dulaglutide compared with short-acting twice daily (bid) exenatide in patients with Type 2 diabetes: A posthoc analysis to determine the influence of baseline HbA1c in the Assessment of Weekly Administration of LY2189265 in Diabetes-1 (AWARD-1) trialDiabetic Medicine20143150
   Web of Science ®Google Scholar